)
4D Molecular Therapeutics (FDMT) investor relations material
4D Molecular Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and business model
Late-stage biotechnology company developing durable, disease-targeted therapeutics using proprietary adeno-associated virus (AAV) vectors from its Therapeutic Vector Evolution (TVE) platform.
Focused on clinical-stage product candidates for retinal and pulmonary diseases with high unmet need, including wet age-related macular degeneration, diabetic macular edema, geographic atrophy, and cystic fibrosis.
Lead candidate 4D-150 targets retinal vascular diseases with a durable, in-office therapy aiming to reduce treatment burden and improve vision outcomes.
Additional pipeline includes 4D-175 for geographic atrophy and 4D-710 for cystic fibrosis, both leveraging proprietary vectors and showing promising clinical or preclinical results.
Financial performance and metrics
Reference is made to financial statements and reports incorporated by reference, including the Annual Report on Form 10-K for the year ended December 31, 2025, and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement for each offering.
- 4D-150 delivers paradigm-shifting durability in retinal disease, reducing injections by over 90%.FDMT
Corporate presentation8 May 2026 - $458M cash supports late-stage trials and operations into H2 2028 despite a $68.8M net loss.FDMT
Q1 20268 May 2026 - Virtual annual meeting to elect directors, ratify auditor, and hold say-on-pay vote.FDMT
Proxy filing28 Apr 2026 - Proxy covers director elections, auditor ratification, say-on-pay, and governance details.FDMT
Proxy filing28 Apr 2026 - 4D-150 delivers paradigm-shifting durability for retinal diseases, reducing treatment burden by up to 92%.FDMT
Corporate presentation18 Mar 2026 - Phase 3 trial enrollment completed early; cash runway extended into H2 2028.FDMT
Q4 202518 Mar 2026 - Phase 3 gene therapy trials for retinal diseases are fully enrolled, with data expected in 2027.FDMT
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - 4D-150's rapid phase III progress and broad commercialization plans highlight strong market potential.FDMT
Leerink Global Healthcare Conference 202610 Mar 2026 - 4D-150 advances in global phase III trials, showing strong safety and reduced treatment burden.FDMT
TD Cowen 46th Annual Health Care Conference3 Mar 2026
Next 4D Molecular Therapeutics earnings date
Next 4D Molecular Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)